 The Core part of the study will be a double-blind except for the use of open label active control moxifloxacin, randomized, placebo-controlled,3 period, 6-sequence, cross-over design in 72 healthy male and female subjects to evaluate whether exenatide at therapeutic and supra-therapeutic concentrations has a pharmacological effect on cardiac repolarization threshold value 10 msec. 